Abiraterone acetate plus prednisolone (AAP) with or without enzalutamide (ENZ) added to androgen deprivation therapy (ADT) compared to ADT alone for men with high-risk non-metastatic (M0) prostate cancer (PCa): Combined analysis from two comparisons in the STAMPEDE platform protocol

Thumbnail
Name:
Publisher version
Thumbnail
Name:
Attard_et_al_Abiraterone_aceta ...
Size:
623.3Kb
Format:
PDF
Download
Cast your vote
 
Your vote was cast
Thank you for your feedback
Authors
Attard, G
Brown, LC
Clarke, N
Murphy, L
Cross, W
Jones, R
Gillessen, S
Russell, JM
Cook, A
Bowen, J
Issue Date
2021-09-01

Metadata
Show full item record
Citation
Attard, G., Brown, L.C., Clarke, N. et al. (2021) Abiraterone acetate plus prednisolone (AAP) with or without enzalutamide (ENZ) added to androgen deprivation therapy (ADT) compared to ADT alone for men with high-risk non-metastatic (M0) prostate cancer (PCa): Combined analysis from two comparisons in the STAMPEDE platform protocol. Annals of Oncology, 32, S5, S1298.
Publisher
Elsevier
Journal
Annals of Oncology
URI
http://hdl.handle.net/2436/624420
DOI
10.1016/j.annonc.2021.08.2098
Additional Links
https://www.annalsofoncology.org/article/S0923-7534(21)04402-1/fulltext#relatedArticles
Type
Other
Language
en
Description
This is an accepted manuscript of an abstract published by Elsevier in Annals of Oncology on 01/09/2021, available online: https://doi.org/10.1016/j.annonc.2021.08.2098 The accepted version of the publication may differ from the final published version.
ISSN
0923-7534
EISSN
1569-8041
Collections
https://creativecommons.org/licenses/by-nc-nd/4.0/
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by-nc-nd/4.0/